pharmaphorum February 13, 2025
A former scientist at Google’s DeepMind who co-developed the AlphaFold2 protein prediction platform, Dr Simon Kohl, has launched his own venture applying artificial intelligence to drug discovery.
Founded in 2023, Latent Labs has now emerged from the shadows with $50 million in start-up financing, including a $40 million Series A co-led by Radical Ventures and Sofinnova Partners.
Its mission is to apply generative AI (GenAI) technologies to build on the predictive capabilities deployed in AlphaFold2 – which earned a Nobel Prize for project co-leads Demis Hassabis and John Jumper – and direct the technology towards the design of new protein-based therapeutics.
Latent Labs said its “generative protein design effort” can help researchers in the biopharma sectors computationally create new therapeutic...
Today's Sponsors
Today's Sponsor